Enliven Therapeutics Inc. (ELVN) - Total Liabilities
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has total liabilities worth $11.49 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Enliven Therapeutics Inc. (ELVN) net asset momentum to track the company's year-over-year net asset growth rate.
Enliven Therapeutics Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Enliven Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Enliven Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Ultrapower Software
SHE:300002
|
China | CN¥1.11 Billion |
|
Atkore International Group Inc
NYSE:ATKR
|
USA | $1.57 Billion |
|
Poco Holding Co Ltd
SHE:300811
|
China | CN¥881.42 Million |
|
Meitu Inc
F:M5U
|
Germany | €3.65 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $940.81 Million |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
China | CN¥2.14 Billion |
|
Ultragenyx
NASDAQ:RARE
|
USA | $1.52 Billion |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
USA | $16.21 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Enliven Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enliven Therapeutics Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 40.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enliven Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual total liabilities of Enliven Therapeutics Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $16.68 Million | +4.78% |
| 2024-12-31 | $15.91 Million | -38.70% |
| 2023-12-31 | $25.96 Million | -83.79% |
| 2022-12-31 | $160.12 Million | +2376.00% |
| 2021-12-31 | $6.47 Million | +0.94% |
| 2020-12-31 | $6.41 Million | +46.21% |
| 2019-12-31 | $4.38 Million | +139.19% |
| 2018-12-31 | $1.83 Million | +23.28% |
| 2017-12-31 | $1.49 Million | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more